PLI Pharma Quarterly Disbursement: DoP Portal Reconciliation

A Tier 2 pharmaceutical applicant on the scale of Ipca Laboratories — a Category 1 PLI Pharma applicant with a Mumbai-headquartered manufacturing footprint spread across Ratlam, Silvassa, Piparia and the Athal Silvassa API campus — closes its Q1 FY 2026-27 quarterly claim on the Department of Pharmaceuticals PLI portal at pliportal.pharmaceuticals.gov.in on 15 July 2026 for the Year 6 disbursement cycle. Document verification by the DoP scheme secretariat runs 30 to 60 days; sanction order and disbursement typically follow 30 to 45 days after verification. An illustrative cumulative Year 6 sanction of Rs 92 crore against the Category 1 per-applicant per-year cap of Rs 100 crore leaves Rs 8 crore of cap headroom that the finance team must track quarter by quarter, reconcile against the Ind AS 20 grant-recognition policy, and feed to the Section 115JB Minimum Alternate Tax book-profit adjustment for the year’s tax provisioning. This is PLI Pharma quarterly disbursement DoP portal reconciliation at operating scale, and the discipline that separates a Year 6 disbursement cycle running on schedule from one where a Q2 query letter delays the sanction into a new financial year is a quarterly disbursement tracker that maps the DoP portal submission log, the document-verification window, the sanction-versus-books reconciling items, and the Ind AS 20 plus Section 115JB accounting overlay in one auditable pack.

The reconciliation in one paragraph

A Category 1 PLI Pharma applicant runs a five-surface quarterly disbursement cycle per scheme year. Surface one is the DoP portal filing calendar — Q1 filed by 15 July, Q2 by 15 October, Q3 by 15 January, Q4 by 15 April, each with a claim workbook, invoice-level sales register, statutory auditor certificate, and identified-product-to-ERP-material-code mapping. Surface two is the document verification tracker maintained during the 30 to 60 day window in which the DoP scheme secretariat and its Project Management Agency verify the submitted documents; a query letter issued during verification resets the clock for the sub-item under query and must be logged with the response track. Surface three is the sanction-versus-books reconciliation — the sanction order issued 30 to 45 days after verification, reconciled to the applicant’s own book-side incentive claim with reconciling items for SKU disallowance, intra-group transfer treatment differences, and applicant-year cap binding. Surface four is the Ind AS 20 grant-recognition entry per the entity’s accounting policy choice — systematic accrual over the eligibility period (Q1 through Q4 as sales are generated) or point-in-time at the DoP sanction date — with the recognition entry driving the Section 115JB MAT book-profit adjustment for the quarter. Surface five is the treasury projection that maps expected sanction and cash-receipt dates against the applicant’s working-capital forecast. Each surface is a distinct reconciliation and each carries its own DoP scrutiny, statutory auditor, and internal audit exposure.

What the scenario looks like in India — the illustrative persona

The Indian pharmaceutical Category 1 PLI applicant universe includes Tier 1 integrated formulators (Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Cipla, Aurobindo Pharma, Lupin, Zydus Lifesciences, Torrent Pharmaceuticals) and Tier 2 speciality and biosimilars developers (Biocon Biologics, Piramal Pharma, Ipca Laboratories, Ajanta Pharma, Alkem Laboratories, Cadila Pharmaceuticals). Each applicant runs a distinct quarterly claim cycle on the DoP PLI portal — separate DoP claim reference number per quarter per scheme year, separate verification window per submission, separate sanction order per approved claim, and separate cash disbursement per sanction. The Year 6 cycle is particularly sensitive because Year 6 sits at the tail of the six-year window with the reduced 6 percent incentive rate (down from 10 percent in Years 1 through 4 and 8 percent in Year 5) and the Rs 100 crore per-applicant per-year cap; every rupee of DoP sanction against the cap counts, and every unresolved reconciling item that delays Q4 sanction into the next financial year moves the receivable balance from FY 2026-27 into FY 2027-28 with attendant Ind AS 20 and Section 115JB implications.

For the illustrative worked example in this article, we take a Category 1 applicant at the scale of a Tier 2 integrated formulator — the Ipca Laboratories persona for a Category 1 applicant running its Year 6 cycle on the DoP portal at an illustrative cumulative sanction of Rs 92 crore against the Rs 100 crore Cat 1 annual cap. The persona is illustrative; real Ipca Labs, or any specific PLI beneficiary’s, Year 6 DoP-sanctioned amounts and per-quarter disbursement calendars are not the subject of speculative recomputation here. The point of the persona is the reconciliation surface, not the identity of any specific real applicant.

The regional pharma manufacturing geography maps to specific plant regions: Baddi in Himachal Pradesh (the excise-legacy formulation cluster), Sikkim (the Section 80-IE legacy cluster), Ahmedabad-Vadodara and Halol (Gujarat integrated pharma), Hyderabad-Bachupally-Bollaram (Telangana and AP API-and-formulation cluster), Ratlam and Piparia (Madhya Pradesh formulation and API), Athal Silvassa (union territory API), Mumbai-Thane (Maharashtra formulation), Kurkumbh (Maharashtra), Verna (Goa), Ankleshwar (Gujarat), and Bengaluru (Karnataka biosimilars and specialty). A PLI Pharma applicant with multi-state manufacturing footprint consolidates the identified-product sales across state GSTINs into a single quarterly claim workbook per scheme year — the DoP portal filing is at the applicant-entity level, not the plant-GSTIN level, and the reconciliation surface aggregates across every plant that supplies an identified product.

The regulatory overlay — DoP scheme SOP, Ind AS 20 recognition timing, Section 115JB MAT

Three regulatory anchors govern the quarterly disbursement chain, and each maps to a distinct reconciliation surface.

The PLI Pharma scheme SOP notified by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers governs the quarterly claim workflow. The claim is filed electronically on the DoP PLI portal at pliportal.pharmaceuticals.gov.in per scheme year per quarter; Q1 (April to June) is due by 15 July, Q2 (July to September) by 15 October, Q3 (October to December) by 15 January, and Q4 (January to March) by 15 April of the following financial year. Each submission includes the invoice-level identified-product sales register for the quarter, the FY 2019-20 base sales allocation cross-check, the incremental sales computation and applicant-year cap binding, and the statutory auditor certificate. The DoP scheme secretariat and its nominated Project Management Agency conduct document verification within 30 to 60 days of filing; a query letter may be issued for clarification and the response resets the verification clock for the sub-item. The sanction order and cash disbursement typically follow 30 to 45 days after successful verification. The end-to-end cycle from Q1 filing to Q1 cash receipt is 60 to 105 days.

Ind AS 20 paragraphs 20 to 22 govern the recognition and presentation of the PLI grant. The grant is classified as a grant related to income (it compensates the applicant for the incremental production and sale of identified products during the scheme window, not for a specific asset acquisition). The recognition timing choice — systematic accrual over the eligibility period as the underlying incremental sales are generated (quarter by quarter through the year) or point-in-time recognition at the DoP sanction date — must be disclosed as an accounting policy in the notes to the financial statements and applied consistently across scheme years. The choice matters because it drives the Section 115JB MAT book-profit adjustment timing. The PLI Pharma Rs 15,000 crore cornerstone walks through the systematic-accrual pattern in detail; the point-in-time-at-sanction pattern is more conservative and more commonly applied where scheme-rule interpretation, DoP-scrutiny outcomes, or intra-group transfer treatment carry material uncertainty.

Section 115JB imposes Minimum Alternate Tax at 15 percent of book profit (plus surcharge and cess) where the tax computed under normal provisions is lower. PLI grant income recognised in the profit and loss statement in a period increases book profit and correspondingly the MAT base — the grant is not currently listed as an exempt item under Explanation 1 to Section 115JB. The quarterly disbursement reconciliation must therefore feed the MAT provisioning workflow with the grant-income leg per quarter, matched to the entity’s Ind AS 20 policy choice. An applicant on the systematic-accrual pattern books the grant quarter by quarter through Q1 through Q4 and provisions MAT quarter by quarter; an applicant on the point-in-time-at-sanction pattern books the grant when the DoP sanction order arrives and concentrates the MAT adjustment in that quarter. Where the applicant has opted into the Section 115BAA concessional 22 percent regime, Section 115JB MAT does not apply — but Section 115BAA restricts the applicant from claiming the Section 35(2AB) R&D weighted deduction, and the trade-off (documented in the Section 35(2AB) weighted deduction pharma R&D reconciliation guide) is a modelling input at scheme entry. Section 92BA intra-group transfer documentation under Rule 10D applies to any backward-integration API supply from a Category 2 API subsidiary to the Category 1 formulation applicant; the DoP portal claim workbook must isolate the intra-group leg with the transfer-pricing documentation reference cited.

A worked example — Year 6 quarterly cycle at 92 percent of Category 1 cap

Illustrative — the following figures represent the operating pattern of a Category 1 PLI Pharma applicant of the scale of a Tier 2 integrated formulator in Year 6 of the scheme window. Public disclosures do not reveal per-quarter DoP-sanctioned amounts for specific applicants; the numbers below are illustrative of the reconciliation surface, not a claim about any specific real applicant’s Year 6 PLI position.

A Category 1 applicant enters Year 6 (FY 2026-27, for an applicant approved in the initial cohort) with the Rs 100 crore per-applicant per-year cap and the Year 6 incentive rate of 6 percent of eligible incremental sales. The applicant’s Year 6 quarterly cycle runs as follows:

The cumulative Year 6 sanction of Rs 92 crore sits Rs 8 crore below the Rs 100 crore Cat 1 per-applicant per-year cap — the applicant’s Year 6 incremental sales did not warrant a raw incentive above the cap, so the cap did not bind. The Q4 sanction of Rs 21 crore and disbursement of 05 July 2027 fall into FY 2027-28 cash flows even though the underlying eligibility period is FY 2026-27; the reconciliation must expose this straddle in the year-end pack. Q2 shows a 55-day verification window because the DoP scheme secretariat issued a query letter on the intra-group API transfer treatment (a Section 92BA specified-domestic-transaction line for the applicant’s Ratlam formulation plant sourcing API from its Athal Silvassa API subsidiary); the applicant’s response to the query — with the Rule 10D transfer-pricing documentation reference and the scheme-rule citation for intra-group inclusion — closed the query and the verification proceeded to sanction.

On the accounting side, the applicant runs a systematic-accrual Ind AS 20 policy — the grant is recognised quarter by quarter as the underlying incremental sales are generated, so the Q1 grant recognition of Rs 22 crore is booked in Q1 (P&L impact April to June 2026) even though the DoP sanction of Rs 22 crore arrives in September 2026. The receivable balance of Rs 22 crore sits on the books from Q1-end (30 June 2026) until the cash receipt on 30 September 2026, at which point the receivable is settled. Section 115JB MAT book-profit adjustment of Rs 22 crore is added to book profit for the Q1 provisioning. The Q4 recognition of Rs 21 crore is more delicate: the eligibility period is January to March 2027 (Q4 FY 2026-27), so the grant is recognised on 31 March 2027 under the systematic-accrual policy, sitting as a receivable balance from 31 March 2027 until cash receipt on 05 July 2027. The receivable carries a year-end audit exposure — the statutory auditor tests reasonable assurance of collection against the DoP portal filing status (filed 15 April 2027, in verification as at balance-sheet date) and the applicant’s compliance history. Section 115JB MAT is provisioned on the Rs 21 crore in FY 2026-27, with the tax being paid in FY 2026-27 self-assessment cycle even though the grant cash is not received until July 2027 — a book-tax timing gap that must be tracked as a deferred tax asset or liability per Ind AS 12.

Across the four quarters, the total Rs 92 crore DoP-sanctioned amount reconciles to Rs 92 crore of Ind AS 20 grant income recognised in FY 2026-27 (systematic-accrual pattern), Rs 92 crore of Section 115JB book-profit adjustment for FY 2026-27, and Rs 71 crore of cash received in FY 2026-27 (Q1 through Q3) with Rs 21 crore of receivable balance carried into FY 2027-28 (Q4). The year-end reconciliation must close all three dimensions to a single audit-defensible number.

Common reconciliation breakages

Five breakages recur across Year 6 PLI Pharma quarterly disbursement cycles, and each maps to a specific control failure.

• Q4 straddle recognition mismatch. The Q4 filing (15 April), verification (30 to 60 days), sanction (30 to 45 days after), and disbursement fall entirely into the following financial year. Applicants that recognise the Q4 grant on cash receipt (following-year FY) rather than on the systematic-accrual pattern (current-year FY Q4) understate current-year Ind AS 20 grant income and correspondingly under-provision Section 115JB MAT — creating a Section 271 income-tax exposure at the statutory audit if the accounting policy is disclosed as systematic accrual. Reconciliation discipline requires the Q4 recognition entry on 31 March per the stated policy, with the receivable balance carried forward to the following year’s opening balance sheet and settled on cash receipt.

• DoP query letter response timing gap. A query letter issued during the 30 to 60 day verification window resets the clock for the sub-item under query. Applicants that delay the response — because the query touches an intra-group Section 92BA transfer treatment, an export-sales exclusion, or a sample-goods carve-out that requires cross-departmental input — push the sanction date beyond the finance team’s forecast, disrupt the treasury projection, and can force the sanction into a following financial year. Reconciliation discipline requires the query letter to be logged in the tracker on issuance with a target response date within seven days, and the response to be routed to the correct owner (indirect-tax lead, plant controller, or transfer-pricing team) with a target closure within 15 days from issuance.

• Sanction-versus-books SKU disallowance untracked. The DoP sanction may exclude an identified-product SKU on grounds of ERP material-code mismatch or delayed DoP notification for a newly launched SKU. Applicants that treat the DoP sanction as the definitive number and write off the shortfall without a reconciling-item tracker lose sight of the SKU-specific issue and repeat the same disallowance in the next quarter. Reconciliation discipline requires every book-versus-sanction difference to be logged as a reconciling item with owner, target closure, and closure status; the closure can be a DoP-notification workflow for a legitimate SKU or a write-off entry for an SKU that will not be added to the DoP-approved list.

• Applicant-year cap binding not modelled forward. The Rs 100 crore per-applicant per-year cap for Category 1 is a hard binding on the Year 6 disbursement. Applicants that do not model the year-to-date claim against the cap headroom quarter by quarter can end Q3 with a raw Q4 incentive that would push the annual claim above Rs 100 crore, only to see the DoP-sanctioned Q4 amount capped at the residual headroom. Reconciliation discipline requires the applicant-year cap tracker to be updated after every sanction with the remaining headroom and the projected Q4 raw incentive; where the projection shows a Q4 cap binding, the excess raw incentive is quantified as foregone and the Ind AS 20 recognition and Section 115JB provisioning are adjusted accordingly. The parallel PLI Pharma incremental sales base year FY 2019-20 reconciliation walkthrough sits alongside this discipline for the incremental-sales side of the cap-binding computation.

• Ind AS 20 policy choice inconsistency year-to-year. Ind AS 20 permits either systematic-accrual over the eligibility period or point-in-time at sanction, but the policy must be applied consistently. Applicants that switch policy mid-year — booking Q1 through Q3 on the systematic-accrual pattern and then deferring Q4 to the point-in-time-at-sanction pattern to defer MAT into the following year — create a policy-inconsistency audit exposure that surfaces at the year-end financial statement review. Reconciliation discipline requires the accounting policy to be disclosed at year-end and applied consistently within the year, with any policy change requiring an Ind AS 8 accounting policy change disclosure with the reason and the retrospective or prospective effect. Terra Insight’s reconciliation failure-mode analysis for India methodology treats the Ind AS 20 recognition-pattern consistency as a specific failure mode with a documented control test.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the DoP portal claim reference master, the quarterly claim workbook, the DoP query letter register, the sanction order feed, and the applicant’s ERP sales ledger and general ledger — and produces a quarterly disbursement pack per quarter per scheme year that closes the loop from DoP portal filing to sanction reconciliation to Ind AS 20 recognition entry to Section 115JB MAT provisioning. The platform tracks the 30 to 60 day verification window per submission, escalates on query letter issuance, and drives the sanction-versus-books reconciliation with a reconciling-item register keyed to SKU disallowance, intra-group treatment differences, and applicant-year cap binding. The Ind AS 20 policy choice (systematic accrual or point-in-time at sanction) is applied consistently across quarters within the year and drives the Section 115JB MAT book-profit adjustment leg per quarter. Match rate improvement of 51 to 88 percent on the DoP sanction to book-side claim reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Category 1 major applicant running a multi-year multi-quarter PLI claim stack rather than a spreadsheet substitute. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform sits at reconciliation software India and the methodology framework for structuring the quarterly disbursement as a controlled reconciliation surface sits in Terra Insight’s reconciliation playbook monthly close pillar.

The five FAQs below address the operational questions pharma controllers and PLI scheme compliance leads ask most often when running the Year 6 quarterly disbursement cycle against the DoP PLI portal.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 16 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024